Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

ClinicalTrials.gov ID: NCT00937950

Public ClinicalTrials.gov record NCT00937950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Gynaecological Follow-up of a Subset of 580299/008 Study Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their last NCT00122681 study visit (Visit 10, Month 48). This follow-up study will also be offered to subjects who were pregnant at their last NCT00122681 study visit (Visit 10, Month 48) so that no cervical sample could be collected at that visit. The objectives \& outcome measures of the primary phase (study 008/580299) are presented in a separate protocol posting (NCT00122681).

Study identification

NCT ID
NCT00937950
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
2,022 participants

Conditions and interventions

Interventions

Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 4, 2009
Primary completion
Jan 19, 2014
Completion
Jan 19, 2014
Last update posted
Oct 28, 2019

2009 – 2014

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
GSK Investigational Site Clearwater Florida 33759
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Honolulu Hawaii 96826
GSK Investigational Site Iowa City Iowa 52242
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Omaha Nebraska 68131
GSK Investigational Site Albuquerque New Mexico 87131
GSK Investigational Site New York New York 10029
GSK Investigational Site Chapel Hill North Carolina 27514
GSK Investigational Site New Bern North Carolina 28562
GSK Investigational Site Tulsa Oklahoma 74105
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Erie Pennsylvania 16507
GSK Investigational Site Erie Pennsylvania 16508
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Pleasant Hills Pennsylvania 15236
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00937950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2019 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00937950 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →